Obstetrics, gynaecology, and urinary tract infections
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
| Daily vs on-demand PDE-5 inhibitors for management of erectile dysfunction following treatment for prostate cancer | Recommendation | Recommended that once daily oral 5mg tadalafil may be considered as an option for the management of erectile dysfunction following treatment for prostate cancer. Oral 2.5mg tadalafil is not recommended by NTAG for this indication on the basis of cost | 07/09/2021 | |
| Dapoxetine for PE | Recommendation | Not recommended | 03/06/2014 | |
|
Updated 22/02/2022 |
Ulipristal (Ellaone®) for post-coital (up to 120 hours) contraception | Recommendation | Recommended as the preferred drug treatment option for post-coital contraception for patients who present between 72 and 120 hours following unprotected intercourse | 22/02/2022 |
| Purewick® female external urinary catheter | Recommendation | Not recommended | 02/06/2020 | |
|
Updated 31/01/2023 |
Vaginal devices for female urinary stress incontinence | NTAG Decision Summary - Vaginal devices for female urinary stress incontinence - updated Noc 2022 - final | Recommended for restricted use. | 15/11/2022 |
|
New 19/05/2023 |
Management of Symptomatic Recurrent Uncomplicated Urinary Tract Infections in Adult Women | recurrent-uti-ics-final-guidance-february-2023 | Approved | 21/02/2023 |